Canavan disease is a rare, inherited brain disorder in which the protective coating around nerve cells breaks down, leading to severe developmental problems in infancy. It belongs to a group of conditions called leukodystrophies, all of which damage the brain’s white matter. Most children show symptoms within the first six months of life, and the most common form progresses quickly, with life-threatening complications typically developing by age 10.
What Happens in the Brain
The brain relies on a fatty insulation called myelin to wrap around nerve fibers and allow signals to travel quickly between cells. In Canavan disease, the cells responsible for building and maintaining that insulation (called oligodendrocytes) can’t do their job. The root cause is a missing or broken enzyme that normally breaks down a molecule called NAA, one of the most abundant chemicals in the brain. Without the enzyme, NAA builds up to toxic levels, and oligodendrocytes fail to properly coat nerve fibers. The result is widespread damage to the brain’s white matter, which is almost entirely made of myelinated nerve fibers.
Because NAA can’t be processed in the brain, the body tries to clear it through the bloodstream and kidneys. This is why children with Canavan disease have abnormally high levels of NAA in both their blood and urine, a finding that helps confirm the diagnosis.
Genetics and Carrier Frequency
Canavan disease is caused by mutations in the ASPA gene, located on chromosome 17. The condition is recessive, meaning a child must inherit a faulty copy from each parent to be affected. Parents who carry one faulty copy and one working copy are healthy carriers with no symptoms.
The disease occurs most frequently among people of Ashkenazi Jewish descent, where roughly 1 in 57 individuals is a carrier. In the general population, the carrier rate is about 1 in 159. Within the Ashkenazi Jewish population, two specific mutations account for approximately 97 to 98 percent of disease-causing gene copies, reflecting a strong founder effect. A different mutation is more common among Europeans without Ashkenazi Jewish ancestry.
Carrier screening is available through a simple blood test and is ideally done before pregnancy. The American College of Obstetricians and Gynecologists recommends that all women considering pregnancy or currently pregnant receive information about genetic carrier screening. If both partners turn out to be carriers, genetic counseling can walk through the options, including prenatal diagnosis.
Early Signs and Symptoms
Babies with Canavan disease typically appear healthy at birth. Symptoms begin between birth and six months of age, when developmental progress stalls or never reaches the milestones expected in the first year. In a study of 23 cases published in the Orphanet Journal of Rare Diseases, every child showed between 2 and 12 symptoms within the first six months. The most common early signs were developmental delay, an unusually large head (macrocephaly), and abnormal eye movements such as involuntary flickering of the eyes or an inattentive gaze.
Macrocephaly becomes noticeable between about 4 and 18 months, with the average onset around 7 months in girls and 8.5 months in boys. Head growth then plateaus around 18 months. This combination of stalled development and a rapidly growing head is the clinical hallmark that distinguishes Canavan disease from many other infantile brain conditions, including cerebral palsy and Krabbe disease.
As the disease progresses, children develop a characteristic pattern of floppy trunk muscles alongside stiff limbs. Many also experience heightened sensitivity to noise early on, though this often fades over time. Seizures, feeding difficulties, and loss of any skills that were gained are common as children grow older. Psychomotor development in affected children is generally limited to abilities normally acquired within the first year of life.
How It’s Diagnosed
Diagnosis usually involves three pieces of evidence: clinical symptoms, brain imaging, and biochemical or genetic testing.
On an MRI, Canavan disease produces a distinctive pattern. The white matter throughout the upper brain shows widespread abnormal signals, reflecting the loss of myelin. The deep gray structures called the globus pallidus, thalamus, and a structure in the cerebellum called the dentate nucleus are commonly involved. Notably, two other deep brain structures (the caudate nucleus and putamen) are typically spared, which helps radiologists distinguish Canavan disease from other white matter disorders. In more advanced cases, the damaged white matter can develop a sieve-like or “cribriform” appearance, with small cyst-like structures radiating outward through the brain tissue.
A urine test showing elevated NAA is a strong biochemical marker. The definitive diagnosis comes from genetic testing that identifies two disease-causing mutations in the ASPA gene.
Disease Course and Life Expectancy
Canavan disease has two recognized forms. The infantile form is far more common and more severe. Children with this type typically worsen quickly and develop life-threatening complications by around age 10. Many survive into their teens, and some into their twenties, but the disease is progressive and there is currently no cure.
A milder juvenile form also exists. It causes less severe neurological problems and is associated with a normal life expectancy. This form is linked to ASPA mutations that reduce enzyme activity without eliminating it entirely.
Supportive Care
Because no approved treatment can reverse the brain damage, care focuses on managing symptoms and maintaining quality of life. Children with Canavan disease often need help with feeding, sometimes requiring a tube placed directly into the stomach to ensure adequate nutrition. Physical therapy helps manage muscle stiffness and maintain as much mobility as possible. Seizures, when they occur, are treated with standard anti-seizure approaches. Care typically involves a team spanning neurology, nutrition, physical and occupational therapy, and palliative support.
Gene Therapy Progress
The most promising experimental treatment is gene therapy designed to deliver a working copy of the ASPA gene directly to the brain cells that need it most. A phase 1/2 clinical trial (registered as NCT04833907) tested a new approach using a viral delivery system engineered to specifically target oligodendrocytes, the exact cell type that fails in Canavan disease. Eight children received a single dose injected into the brain.
At the 12-month interim analysis, the results were encouraging. NAA levels in spinal fluid dropped significantly, indicating the replacement gene was producing functional enzyme. Myelination increased on brain imaging, and developmental assessments showed measurable improvement. The treatment was well tolerated. While these results are preliminary and the trial is small, they represent the most direct evidence yet that replacing the missing enzyme in the right cells can begin to address the underlying biology of the disease. Researchers have noted these findings could also inform gene therapy strategies for other conditions involving myelin loss.